

15 November 2022

LungLife AI, Inc.

("LungLife" or the "Company")

Block Listing Six Monthly Return

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six-monthly update on its block listing:

Name of applicant:		LungLif	e Al, Inc.		
Name of scheme:		 2010 Stock Incentive Plan 2020 Stock Incentive Plan 2021 Omnibus Long-Term Incentive Plan 			
Number and class of securities originally admitted:		1,356,139 common shares of US \$0.0001 each			
Date of admission:		15 November 2021			
Period of return:	From:	15 May	2022	To:	15 November 2022
Balance of unallotted securities under scheme(s) from previous return:		1. 2. 3.	480,775 201,374 673,990		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1. 2. 3.	NIL NIL NIL		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		1. 2. 3.	5,192 NIL NIL		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		1. 2. 3.	475,583 201,374 673,990		

Name of contact:	David Anderson, Chief Financial Officer
Telephone number of contact:	+44 (0)20 7933 8780
	or <u>lunglifeai@walbrookpr.com</u>

For further information please contact:

LungLife AI, Inc.Paul Pagano, CEO
David Anderson, CFO

www.lunglifeai.com
Via Walbrook PR

Investec Bank plc (Nominated Adviser & Broker)

Daniel Adams / Virginia Bull / Cameron MacRitchie

Walbrook PR Limited

Paul McManus / Alice Woodings / Phil Marriage

Tel: +44 (0)20 7933 8780 or <u>LungLifeAl@walbrookpr.com</u>

Tel: +44 (0)20 7597 5970

Mob: 07980 541 893 / 07407 804 654 / +44 07867 984 082